✉ Email this page to a colleague
« Back to Dashboard
Hysingla is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twenty-two patents protecting this drug.
The generic ingredient in HYSINGLA is hydrocodone bitartrate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.
A generic version of HYSINGLA was approved as hydrocodone bitartrate by ALVOGEN on January 21st, 2020.